重庆医学Issue(18)：2294-2296,3.DOI:10.3969/j.issn.1671-8348.2014.18.012
洛铂联合伊立替康二线治疗小细胞肺癌的临床研究
Clinical study of lobaplatin or cisplatin combined with irinotecan in treating small cell lung cancer
汪晓洁 1寿涛 1李丽华 1缪堃 1陈庆 2陈雪丹2
作者信息
- 1. 云南省第一人民医院肿瘤综合治疗中心/昆明理工大学附属医院，昆明 650032
- 2. 云南省红河州第三人民医院肿瘤内科，云南个旧 661000
- 折叠
摘要
Abstract
Objective To observe the effect and adverse reactions of lobaplatin or cisplatin combined with irinotecan(CPT-11)in the second line treatment of small cell lung cancer(SCLC).Methods 5 6 cases of SCLC failed in the first line treatment scheme of etoposide combined with cisplatin and progressed within 3-6 months were randomized into the lobaplatin group (lobaplatin +CPT-11)and the cisplatingroup(cisplatin+CPT-11).The lobaplatin group:lobaplatin 30 mg/m2 by intravenous drip on d 1,and CPT-11 65 mg/m2 by intravenous drip on d 1,8.The cisplatin group:cisplatin 25 mg/m2 by intravenous drip on d 2,3,4,and CPT-11 65 mg/m2 by intravenous drip on d 1,8.After more than 2 cycles of chemotherapy,the therapeutical effects were evaluated.The short term effects and the toxic and side effects were compared between the two groups.Furthermore,the time to progression (TTP)and the overall survival(OS).Results In the lobaplatin group(30 cases),the overall response rate(RR)was 36.7% with the disease control rate (DCR)of 66.7%;in the cisplatin group(26 cases),the overall RR was 34.6% with DCR of 65.4%,the difference between the two groups had no statistical significance(P>0.05).The median TTP and OS were 4.5 months and 8.5 months in the lobaplatin group,while which were 4.3 months and 8.4 months in the cisplatin group respectively,the difference in the overall RR and DCR between the two groups had no statistical significance(P>0.05)The main toxicity in the lobaplatin groups was bone marrow depression and which in the cisplatin group were the digestive tract reaction and bone marrow depression without statistical differences between the two groups(P>0.05).The occurrence rate of degreeⅢ-Ⅳ of nausea and vomiting in the cispl-atin group was significantly higher than that in the lobaplatin group with statistical difference between the two groups(P<0.05). Conclusion lobaplatin combined with CPT-1 1 as the second line treatment of SCLC has definite effect with tolerable toxicity reac-tion;compared with the scheme of cisplatin plus CPT-1 1 ,the effect is similar,which deserves to be further studied and observed.关键词
小细胞肺癌/洛铂/顺铂/伊立替康Key words
small-cell-lung-cancer/lobaplatin/cisplatin/irinotican引用本文复制引用
汪晓洁,寿涛,李丽华,缪堃,陈庆,陈雪丹..洛铂联合伊立替康二线治疗小细胞肺癌的临床研究[J].重庆医学,2014,(18):2294-2296,3.
